Eli Lilly's obesity drug Zepbound can now be covered by government-backed Medicare insurance plans for use in sleep apnea, broadening access to the blockbuster weight-loss treatment.
<p>WASHINGTON — Eli Lilly's obesity drug Zepbound can now be covered by government-backed Medicare insurance plans for use in sleep apnea, broadening access to the blockbuster weight-loss treatment.
</p><p>Insurers can still choose not to cover Zepbound despite the Centers for Medicare and Medicaid Services's guidance.
Traffic Weather Sports Classifieds Cars Jobs Homes Television Radio Salt Lake Utah Local
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Medicare to Cover Eli Lilly's Obesity Drug Zepbound for Sleep ApneaMedicare Part D plans can now cover Eli Lilly's obesity drug Zepbound for patients with obstructive sleep apnea (OSA), expanding access to the medication. This coverage decision follows the FDA's recent approval of Zepbound for treating both obesity and moderate-to-severe OSA.
Read more »
Medicare Now Covers Eli Lilly's Obesity Drug Zepbound for Sleep ApneaMedicare Part D plans can now cover Eli Lilly's obesity drug Zepbound for patients with obstructive sleep apnea, expanding its accessibility.
Read more »
FDA approves Eli Lilly's Zepbound for sleep apnea treatmentThe FDA granted approval to Eli Lilly's weight-loss drug Zepbound for treating sleep apnea, marking a significant advancement in managing this prevalent condition.
Read more »
FDA approves Eli Lilly's weight loss drug Zepbound for sleep apnea, expanding use in U.S.The agency’s decision expands the use of Zepbound and could potentially pave the way for Eli Lilly to gain broader insurance coverage for the treatment.
Read more »
FDA says Eli Lilly's weight loss drug Zepbound is no longer in shortageThe decision that will eventually bar compounding pharmacies from making unbranded versions of the injection.
Read more »
Eli Lilly's Zepbound Anti-Obesity Drug Poised to Drive Healthcare CostsEli Lilly & Co.'s weight-loss drug Zepbound is predicted to significantly impact healthcare costs for insurers, employers, and government programs. Already, GLP-1 drugs like Wegovy and Ozempic are major cost drivers, and Zepbound's superior efficacy and market expansion are expected to further increase expenses. Analysts project that Zepbound will dominate the obesity market, surpassing Novo Nordisk's Wegovy, leading to substantial increases in healthcare inflation.
Read more »